8h agoRaj Batra MD warns FDA review delays are ceding US biotech leadership to AsiaAsian competitors are approving high-risk experiments like xenobiotic chimeras.SentimentSentimentPos0%Neg100%Many users called the FDA's clinical trial process an absolute contradictory mess causing major delays that worsen US biotech competitiveness versus China, with some urging reduced agency authority.3 comments with sentiment. View comments.